Cochrane · systematic review · CD008605
Dopamine agonists for preventing ovarian hyperstimulation syndrome
Tang, H, Mourad, SM., Wang, A, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
17
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 5.6%Very low 5 · 27.8%Low 10 · 55.6%Moderate 2 · 11.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyDopamine agonist versus placebo/no intervention
Population: women of reproductive age undergoing any ART therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of moderate or severe OHSS Dopamine agonist vs placebo/no intervention | OR 0.32 [0.23, 0.44] | 10 studies · 1202 participants | Moderate Downgraded: risk of bias |
Live birth rate Dopamine agonist vs placebo/no intervention | OR 0.96 [0.6, 1.55] | 3 studies · 362 participants | Low Downgraded: risk of bias, imprecision |
Clinical pregnancy rate Dopamine agonist vs placebo/no intervention | OR 0.92 [0.63, 1.37] | 5 studies · 530 participants | Low Downgraded: risk of bias, imprecision |
Multiple pregnancy rate Dopamine agonist vs placebo/no intervention | OR 0.32 [0.01, 8.26] | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Miscarriage rate Dopamine agonist vs placebo/no intervention | OR 0.66 [0.19, 2.28] | 2 studies · 168 participants | Low Downgraded: risk of bias, imprecision |
Any other adverse events Dopamine agonist vs placebo/no intervention | OR 4.54 [1.49, 13.84] | 2 studies · 264 participants | Very low Downgraded: risk of bias, imprecision |
Dopamine agonist plus co‐intervention versus co‐intervention
Population: women of reproductive age undergoing any ART therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of moderate or severe OHSS Dopamine agonist plus co‐intervention vs co‐intervention | OR 0.48 [0.28, 0.84] | 4 studies · 748 participants | Low Downgraded: risk of bias, imprecision |
Live birth rate Dopamine agonist plus co‐intervention vs co‐intervention | OR 1.21 [0.81, 1.8] | 2 studies · 400 participants | Low Downgraded: risk of bias, imprecision |
Clinical pregnancy rate Dopamine agonist plus co‐intervention vs co‐intervention | OR 1.11 [0.83, 1.49] | 4 studies · 748 participants | Low Downgraded: risk of bias, imprecision |
Multiple pregnancy rate Dopamine agonist plus co‐intervention vs co‐intervention | OR 2.02 [0.18, 22.77] | 1 study · 166 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Miscarriage rate Dopamine agonist plus co‐intervention vs co‐intervention | OR 0.65 [0.3, 1.42] | 3 studies · 548 participants | Low Downgraded: risk of bias, imprecision |
Any other adverse events Dopamine agonist plus co‐intervention vs co‐intervention | OR 3.03 [0.12, 75.28] | 2 studies · 366 participants | Very low Downgraded: risk of bias, imprecision |
Dopamine agonist versus other active intervention
Population: women of reproductive age undergoing any ART therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of moderate or severe OHSS Dopamine agonist vs other active intervention | OR 0.21 [0.12, 0.38] | 3 studies · 296 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Live birth rate Dopamine agonist vs other active intervention | OR 1.08 [0.73, 1.59] | 2 studies · 430 participants | Low Downgraded: risk of bias, imprecision |
Clinical pregnancy rate Dopamine agonist vs other active intervention | OR 1.04 [0.81, 1.33] | 7 studies · 1060 participants | Moderate Downgraded: risk of bias |
Multiple pregnancy rate Dopamine agonist vs other active intervention | OR 0.87 [0.47, 1.59] | 3 studies · 400 participants | Low Downgraded: risk of bias, imprecision |
Miscarriage rate Dopamine agonist vs other active intervention | OR 0.66 [0.35, 1.25] | 4 studies · 630 participants | Low Downgraded: risk of bias, imprecision |
Any other adverse events Dopamine agonist vs other active intervention | no estimate extracted | 1 study · 170 participants | Ungraded |
Dopamine agonist versus placebo/no intervention
Population: women of reproductive age undergoing any ART therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of moderate or severe OHSS Dopamine agonist vs placebo/no intervention | OR 0.27 [0.19, 0.39] | 8 studies · 1022 participants | Moderate Downgraded: risk of bias |
Live birth rate Dopamine agonist vs placebo/no intervention | OR 1.01 [0.53, 1.91] | 1 study · 182 participants | Low Downgraded: risk of bias |
Clinical pregnancy rate Dopamine agonist vs placebo/no intervention | OR 0.81 [0.54, 1.22] | 4 studies · 432 participants | Moderate Downgraded: risk of bias |
Multiple pregnancy Dopamine agonist vs placebo/no intervention | OR 0.32 [0.01, 8.26] | 1 study · 40 participants | Very low Downgraded: risk of bias |
Miscarriage pregnancy rate Dopamine agonist vs placebo/no intervention | OR 0.66 [0.19, 2.28] | 2 studies · 168 participants | Low Downgraded: risk of bias |
Adverse events Dopamine agonist vs placebo/no intervention | OR 4.54 [1.49, 13.84] | 2 studies · 264 participants | Very low Downgraded: risk of bias |
Cabergoline versus control for preventing OHSS
Population: Women of reproductive age undergoing any assisted reproductive technology (ART) therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of OHSS Cabergoline vs control | OR 0.4 [0.2, 0.77] | 2 studies · 230 participants | Low |
Incidence of severe OHSS Cabergoline vs control | OR 0.77 [0.24, 2.45] | 2 studies · 230 participants | Low |
Incidence of moderate OHSS Cabergoline vs control | OR 0.38 [0.19, 0.78] | 2 studies · 230 participants | Low |
Clinical pregnancy rate Cabergoline vs control | OR 0.94 [0.56, 1.59] | 2 studies · 230 participants | Low |
Miscarriage rate Cabergoline vs control | RR 0.31 [0.03, 3.07] | 1 study · 163 participants | Low |
Side effects Cabergoline vs control | OR 2.07 [0.56, 7.7] | 1 study · 67 participants | Low |